On August 13, 2020 Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, reported that it participated in Canaccord Genuity’s 40th Annual Growth Conference in a Fireside Chat today at 10:30 am ET (Press release, Palatin Technologies, AUG 13, 2020, View Source [SID1234563612]). The conference was held virtually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Carl Spana, Ph.D., President and Chief Executive Officer and Stephen T. Wills, Chief Financial Officer and Chief Operating Officer of Palatin Technologies, participated in the Fireside Chat hosted by John Newman of Canaccord Genuity.

The Fireside Chat was webcast. The webcast replay can be accessed by logging on to the "Investor/Webcasts" section of Palatin’s website at View Source or by clicking the following link: View Source The webcast will be available for 90 days.